Aua Capital Management LLC Lowers Stock Position in Johnson & Johnson (NYSE:JNJ)

Aua Capital Management LLC reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 5.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,363 shares of the company’s stock after selling 130 shares during the quarter. Aua Capital Management LLC’s holdings in Johnson & Johnson were worth $342,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the business. Hager Investment Management Services LLC acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $297,000. Cassia Capital Partners LLC lifted its position in Johnson & Johnson by 59.5% during the fourth quarter. Cassia Capital Partners LLC now owns 5,538 shares of the company’s stock worth $801,000 after buying an additional 2,065 shares in the last quarter. Avitas Wealth Management LLC grew its holdings in shares of Johnson & Johnson by 0.6% in the fourth quarter. Avitas Wealth Management LLC now owns 30,181 shares of the company’s stock valued at $4,365,000 after purchasing an additional 182 shares during the period. Redwood Wealth Management Group LLC grew its stake in shares of Johnson & Johnson by 3.2% in the 4th quarter. Redwood Wealth Management Group LLC now owns 4,020 shares of the company’s stock valued at $580,000 after buying an additional 124 shares during the period. Finally, Bay Harbor Wealth Management LLC acquired a new stake in Johnson & Johnson during the fourth quarter worth $32,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $153.10 on Friday. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $168.85. The firm’s fifty day simple moving average is $147.46 and its 200-day simple moving average is $156.06. The stock has a market cap of $368.61 billion, a PE ratio of 23.02, a price-to-earnings-growth ratio of 2.44 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The company had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The company’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same period last year, the firm earned $2.29 EPS. Analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.24%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

Insider Buying and Selling

In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of Johnson & Johnson stock in a transaction on Thursday, December 12th. The shares were bought at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $147,220. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on JNJ shares. Argus raised shares of Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. Citigroup lowered their target price on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 16th. Wells Fargo & Company decreased their target price on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Finally, Guggenheim raised their price objective on Johnson & Johnson from $162.00 to $166.00 and gave the stock a “neutral” rating in a report on Monday, February 3rd. Nine analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus price target of $170.67.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.